Skyhawk's Huntington's Drug Shows Significant Efficacy in Phase 1/2 Trial
Event summary
- Skyhawk's SKY-0515 showed a +1.59-point improvement in cUHDRS vs. controls at 15 months.
- All four cUHDRS components (function, motor, cognition) favored SKY-0515 statistically.
- 9 mg dose reduced mutant huntingtin protein by >60% and PMS1 mRNA by >25%.
- Phase 2/3 FALCON-HD trial has enrolled over 200 patients across 10 countries.
The big picture
Skyhawk's results position SKY-0515 as a potential breakthrough in Huntington's disease, a field with no approved disease-modifying therapies. The dual mechanism targeting mutant huntingtin and PMS1 sets it apart, while the oral, once-daily administration could expand patient access. Success in the Phase 2/3 trial would validate Skyhawk's SKYSTAR platform for other neurodegenerative indications.
What we're watching
- Clinical Validation
- Whether the Phase 2/3 FALCON-HD trial confirms these results, validating SKY-0515 as a potential disease-modifying therapy for Huntington's.
- Regulatory Pathway
- The pace at which Skyhawk can advance SKY-0515 through regulatory approvals, given the unmet need in Huntington's disease.
- Platform Potential
- How Skyhawk's SKYSTAR platform will be leveraged for other rare neurological diseases, following this proof-of-concept.
Related topics